(CercleFinance.com) – Bayer today announced Japanese health authorities have approved treatment with Elyea (aflibercept) by intravitreal injection for the treatment of premature infants with retinopathy of prematurity (ROP).
‘ Retinopathy of prematurity is a disease that affects premature babies and severe forms can lead to significant visual impairment and even blindness. Prompt treatment of this vulnerable pediatric patient population is crucial,” said Dr. Michael Devoy, Chief Medical Officer at Bayer.
‘Treatment success with Eylea 0.4mg was high as expected and mostly achieved with a single injection per eye,’ adds Dr. Noriyuki Azuma, study investigator and president of the Japanese Association pediatric ophthalmology.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
